Cerevel Therapeutics Holdings, Inc. (CERE)

NASDAQ: CERE · IEX Real-Time Price · USD
42.11
-0.03 (-0.07%)
Apr 19, 2024, 1:35 PM EDT - Market open
-0.07%
Market Cap 7.65B
Revenue (ttm) n/a
Net Income (ttm) -432.84M
Shares Out 181.58M
EPS (ttm) -2.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 317,630
Open 42.01
Previous Close 42.14
Day's Range 42.00 - 42.19
52-Week Range 19.59 - 43.59
Beta 1.49
Analysts Hold
Price Target 40.36 (-4.16%)
Earnings Date May 1, 2024

About CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selectiv... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 334
Stock Exchange NASDAQ
Ticker Symbol CERE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CERE stock is "Hold." The 12-month stock price forecast is $40.36, which is a decrease of -4.16% from the latest price.

Price Target
$40.36
(-4.16% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study

Cerevel Therapeutics said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial.

1 day ago - Reuters

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with p...

1 day ago - GlobeNewsWire

CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in...

3 months ago - Business Wire

Cramer names biopharma companies to watch as industry mergers start to pile up

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Other symbols: ABBVAMGNAZNBMYPFERHHBY
3 months ago - CNBC

CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cerevel Therapeu...

Other symbols: ABBV
4 months ago - Business Wire

AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio

Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.

Other symbols: ABBV
4 months ago - Investopedia

AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say

AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks...

Other symbols: ABBV
4 months ago - Reuters

Cramer reacts to AbbVie buying Cerevel Therapeutics

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) jumped some 12% today after AbbVie Inc (NYSE: ABBV) said it will buy the drug company that focuses primarily on neurological disorders. AbbVie seems to...

Other symbols: ABBV
4 months ago - Invezz

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion

CNBC's David Faber delivers his latest Faber Report.

Other symbols: ABBV
4 months ago - CNBC Television

Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout

U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals...

Other symbols: ABBV
4 months ago - Reuters

Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair Price in its transaction with AbbVie

MILWAUKEE , Dec. 6, 2023 /PRNewswire/ -- Ademi LLP is investigating Cerevel (NASDAQ: CERE) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click her...

4 months ago - PRNewsWire

CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics

NEW YORK , Dec. 6, 2023 /PRNewswire/ -- Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, In...

4 months ago - PRNewsWire

Cerevel options trading surge before AbbVie deal news raises eyebrows

Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer...

Other symbols: ABBV
4 months ago - Reuters

AbbVie to buy drug developer Cerevel for $8.7 billion

AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Hum...

Other symbols: ABBV
4 months ago - Reuters

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's “robust” neuroscience pipeline adds medications that may transform stand...

Other symbols: ABBV
4 months ago - Market Watch

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage pipeline...

Other symbols: ABBV
4 months ago - PRNewsWire

Exclusive: AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources

AbbVie Inc is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc , a developer of drugs for neurological conditions such as Parkinson's, people familiar with the mat...

Other symbols: ABBV
4 months ago - Reuters

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson's Disease

Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson's disease

5 months ago - GlobeNewsWire

Cerevel Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced th...

5 months ago - GlobeNewsWire

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track...

6 months ago - GlobeNewsWire

Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...

6 months ago - GlobeNewsWire

Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, ann...

6 months ago - GlobeNewsWire

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, ann...

6 months ago - GlobeNewsWire

Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that me...

8 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE).  Such investo...

8 months ago - PRNewsWire